Does a resistant hypertension diagnosis mean my medicines do not work?

No. It describes a level of treatment intensity, not drug failure. Your drugs are almost certainly lowering your pressure, just not to goal yet. The label is a signal to look for a hidden driver and to add a fourth agent, not a reason to stop what you take.

Can a home blood pressure monitor help confirm or rule out the diagnosis?

Yes. The 2018 AHA statement requires excluding the white-coat effect, which means comparing office readings with home or 24-hour ambulatory readings. If your out-of-office numbers sit at or below target, the resistance is white-coat rather than true. Bring your log to the appointment.

Should everyone with resistant hypertension be tested for a hormone problem?

The 2025 AHA/ACC hypertension guideline says yes for primary aldosteronism, and it drops the old requirement of low potassium first. Initial testing is a blood draw for plasma aldosterone and renin. Fewer than 2% of eligible patients currently get screened, so it is reasonable to ask directly.

Will stopping ibuprofen lower my blood pressure?

It may help, since NSAIDs are the medications most commonly implicated in drug-induced blood pressure elevation and they cause sodium and water retention. The size of the effect varies by person. Ask your clinician before stopping any pain medication, and discuss alternatives for the underlying pain.

What Is Resistant Hypertension And What Causes It?

Q: Is resistant hypertension actually more dangerous than ordinary high blood pressure?

The risk is higher. In a cohort of 2,016 hypertensive participants, both the 2008 and the 2018 definitions predicted major adverse cardiovascular events and renal events over a median 4.5 years. That is the reason guidelines push for a real workup instead of simply adding another pill.

The short answer: Resistant hypertension means blood pressure stays above goal while you take three antihypertensive drug classes at maximum or maximally tolerated doses, usually including a diuretic. It also covers people whose blood pressure is at goal but only on four or more drugs. The label applies only after a clinician confirms you actually take the pills and rules out the white-coat effect. Most people with true resistance have a driver behind it, such as primary aldosteronism, sleep apnea, kidney disease, or a drug that raises blood pressure.

What counts as resistant hypertension?

The formal definition comes from the 2018 American Heart Association scientific statement on resistant hypertension. It defines resistant hypertension as blood pressure above goal despite the concurrent use of three antihypertensive drug classes. The statement describes the usual trio as a long-acting calcium channel blocker, a blocker of the renin-angiotensin system (an ACE inhibitor or an ARB), and a diuretic.

Two details matter. All three drugs must be at maximum or maximally tolerated daily doses, so three low-dose drugs do not qualify. And blood pressure controlled only with four or more drugs also counts as resistant.

A diuretic is expected rather than optional in practice. A 2025 review of resistant hypertension epidemiology and treatment describes optimal triple therapy as an ACE inhibitor or ARB, a calcium channel blocker, and a thiazide or thiazide-like diuretic, all at maximum or maximally tolerated doses. The 2018 statement also lowered the threshold that defines "above goal" to 130/80 mm Hg, down from 140/90 mm Hg in the earlier 2008 version, as a 2021 analysis of the redefinition explains.

How is apparent resistant hypertension different from true resistance?

"Apparent" resistant hypertension is what the numbers alone show: the drug count and the office readings fit, but nobody has checked adherence or out-of-office pressure. True resistant hypertension is what remains after you strip those two explanations away.

Nonadherence is the bigger of the two. A systematic review and meta-analysis of 42 studies and 71,353 patients found a pooled nonadherence prevalence of 37% (95% CI 27% to 47%) in apparent resistant hypertension. Detection method mattered a great deal. Direct methods, such as urine or blood drug assays and directly observed therapy, found 46% (95% CI 40% to 52%). Indirect methods, such as pill counts and questionnaires, found only 20% (95% CI 11% to 35%).

The white-coat effect is the second explanation. Office readings above goal with home or 24-hour readings at or below target point to white-coat resistance, not true resistance. Our guide to white coat hypertension covers how clinicians separate the two. Bad cuff technique and under-dosing count as pseudoresistance too.

How common is resistant hypertension?

Estimates depend heavily on the definition and on whether adherence was verified. In a National Health and Nutrition Examination Survey analysis of 4,158 US adults taking antihypertensive medication in 2009 to 2014, apparent treatment-resistant hypertension affected 17.7% under the 2008 definition and 19.7% under the 2018 definition. That is roughly 9.2 million and 10.3 million US adults.

Other datasets land lower. A meta-analysis of 3.2 million patients put the prevalence at about 10% of treated hypertension, and US estimates across studies range from 8.5% to 20%, per the 2025 epidemiology review. A separate cohort of 2,016 hypertensive participants found 10.2% under the 2008 threshold and 13.7% under the 2018 threshold.

This group carries real risk. In that cohort, both definitions predicted major adverse cardiovascular events and renal events over a median 4.5 years.

Which secondary causes are worth working up?

Resistant hypertension raises the odds that something identifiable is driving the pressure. The short list: primary aldosteronism, obstructive sleep apnea, renal artery disease, chronic kidney disease, pheochromocytoma, thyroid disease, and Cushing syndrome.

Primary aldosteronism. It accounts for about 5% to 10% of all hypertension and up to 20% of resistant hypertension, according to a 2026 summary of the 2025 AHA/ACC hypertension guideline. A 2026 review of screening alignment cites figures up to 25%. It is the most commonly found treatable hormonal cause.
Obstructive sleep apnea. The 2025 epidemiology review reports sleep apnea in 50% to 70% of people with resistant hypertension, which makes it the most common comorbid finding. See our page on sleep apnea and high blood pressure.
Kidney causes. The same review reports chronic kidney disease in 10.3% to 22.9% and renal artery stenosis in 5% to 20%. Across all ages, renal parenchymal disease remains the most common cause of secondary hypertension overall, per the NIH Bookshelf StatPearls review of secondary hypertension.

Screening for aldosterone excess is the biggest recent change. The 2025 AHA/ACC guideline recommends screening every adult with resistant hypertension for primary aldosteronism, regardless of serum potassium, because most cases do not cause low potassium. Real-world screening lags badly. Among more than 200,000 US veterans with apparent treatment-resistant hypertension, fewer than 2% were screened.

Which drugs and substances push blood pressure up?

A medication review belongs in every workup. The StatPearls secondary hypertension review calls nonsteroidal anti-inflammatory drugs "the most commonly implicated medications due to their widespread use," because they cause sodium and water retention.

Decongestants and other sympathomimetics. Phenylephrine and pseudoephedrine constrict blood vessels. The NIH MedlinePlus page for pseudoephedrine tells patients to tell their doctor about any history of high blood pressure or heart disease before use.
Estrogen-containing contraceptives. StatPearls cites an incidence of significant hypertension under 1% after one year of use and about 2% after five years.
Licorice. Glycyrrhizin acts like a mineralocorticoid. The NIH National Center for Complementary and Integrative Health notes that even small amounts have been linked to severe adverse effects in people with hypertension and in people who eat a lot of salt. Products at supplements.md are worth checking for licorice root, ephedra, and yohimbine.
Stimulants and some antidepressants. Methylphenidate, amphetamines, cocaine, methamphetamine, nicotine, venlafaxine, and duloxetine all appear on the StatPearls list.
Cancer therapies. VEGF inhibitors raise blood pressure in 25% to 70% of patients, tyrosine kinase inhibitors in 20% to 30%.

Excess alcohol and high sodium intake belong in the same conversation. Both work against every drug in the regimen.

What do guidelines recommend next?

The first moves are basic: confirm adherence, measure blood pressure outside the office, correct cuff technique, and check that the diuretic is right and fully dosed. Chlorthalidone and indapamide are the thiazide-like agents favored in the 2025 review.

Fourth-line therapy is usually a mineralocorticoid receptor antagonist. In the PATHWAY-2 crossover trial of 335 patients with resistant hypertension, spironolactone beat placebo by 8.70 mm Hg in home systolic blood pressure, bisoprolol by 4.48 mm Hg, and doxazosin by 4.03 mm Hg, all with p < 0.001, as summarized by the American College of Cardiology trial review. Potassium and kidney function need monitoring. Our comparison of blood pressure medications covers how the classes differ.

Two new drug classes are now approved, both as add-ons. Aprocitentan (Tryvio), an endothelin receptor antagonist, was first approved in the US in 2024 as a 12.5 mg once-daily tablet for patients not adequately controlled on other drugs. It carries a boxed warning for embryo-fetal toxicity. Baxdrostat (Baxfendy), the first aldosterone synthase inhibitor, was approved in 2026 in 1 mg and 2 mg tablets, also in combination with other antihypertensive drugs.

A device option exists too. The FDA approved two renal denervation systems in November 2023, one radiofrequency and one ultrasound. The 2025 AHA/ACC guideline gives renal denervation a Class 2b recommendation: it may be considered for adults with resistant hypertension despite optimal medical therapy. Expect a modest effect, not a cure. A 2025 review of kidney denervation reports pooled 24-hour ambulatory systolic reductions of 3.7 mm Hg in off-medication trials and 2.3 mm Hg in on-medication trials.

The bottom line

Resistant hypertension is a specific label, not a general description of stubborn blood pressure. It requires three drug classes at maximum or maximally tolerated doses, usually including a diuretic, or four or more drugs to reach goal. Before accepting the label, clinicians should verify adherence and check out-of-office readings, since roughly 37% of apparent cases involve missed doses. The workup is where the value sits: screen for primary aldosteronism regardless of potassium, look for sleep apnea and kidney disease, and audit the medicine cabinet.

Last updated: September 2026. This article is for informational purposes only and does not constitute medical advice. Do not start, stop, or change any blood pressure medication without talking to your clinician.